Among the companies whose shares are making notable moves in Tuesday's session are Afexa Life Sciences Inc. (FXA.T), DiagnoCure Inc. (CUR.T) and Churchill Corp. (CUQ.T).
Afexa (C$0.71, C$0.12, 20%) has agreed to a C$76 million takeover offer from Valeant Pharmaceuticals Inc. (VRX). Valeant's 71-Canadian-cent-a-share offer tops a previous hostile 55-Canadian-cent-a-share bid from Paladin Labs Inc. (PLB.T).
DiagnoCure (C$0.91, -C$0.12, -12%) said the U.S. Food and Drug Administration panel review for the Progensa PCA3 test has been delayed. Its commercial partner, Gen-Probe Inc., now expects the review in the first quarter of 2012. The original date was Oct. 14.
A unit of Churchill Corp. (C$14.87, C$0.42, 2.9%) has received C$158 million of new contracts in British Columbia and Manitoba.
